The stock of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) is a huge mover today! About 64,548 shares traded or 214.09% up from the average. Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) has declined 11.78% since September 14, 2016 and is downtrending. It has underperformed by 22.60% the S&P500.The move comes after 7 months positive chart setup for the $90.14M company. It was reported on Apr, 21 by Barchart.com. We have $7.19 PT which if reached, will make NASDAQ:ORMP worth $5.41 million more.
TOR Minerals International, Inc. is a maker and seller of mineral products for use as pigments and extenders, primarily in the manufacture of paints, industrial coatings plastics, and solid surface applications. The company has market cap of $24.44 million. The Company’s specialty mineral products, which include flame retardant and smoke suppressant fillers, engineered fillers, and titanium dioxide -color hybrid pigments, are designed for use in plastics, coatings, paints and catalysts applications, as well as a range of other industrial applications. It has a 50.94 P/E ratio. The Firm and its subsidiaries operate in the business of pigment manufacturing and related products in three geographic divisions, namely, United States, European and Asian.
Analysts await TOR Minerals International Inc (NASDAQ:TORM) to report earnings on May, 3.
First Wilshire Securities Management Inc holds 0.18% of its portfolio in TOR Minerals International Inc for 103,913 shares. Grt Capital Partners L.L.C. owns 31,077 shares or 0.05% of their US portfolio. Moreover, Acadian Asset Management Llc has 0% invested in the company for 68 shares. The Delaware-based Blackrock Advisors Llc has invested 0% in the stock. Blackrock Fund Advisors, a California-based fund reported 263 shares.
About 162 shares traded. TOR Minerals International Inc (NASDAQ:TORM) has risen 33.40% since September 14, 2016 and is uptrending. It has outperformed by 22.57% the S&P500.
Oramed Pharmaceuticals Inc. is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. The company has market cap of $90.14 million. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. It currently has negative earnings. The Firm is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Investors sentiment increased to 1.25 in Q4 2016. Its up 0.81, from 0.44 in 2016Q3. It is positive, as 1 investors sold Oramed Pharmaceuticals, Inc. shares while 3 reduced holdings. 4 funds opened positions while 1 raised stakes. 109,206 shares or 33.39% less from 163,943 shares in 2016Q3 were reported. Joel Isaacson And owns 700 shares for 0% of their portfolio. Financial Bank Of America De invested 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). 2,000 are held by Financial Architects Inc. Gru One Trading Lp, a Illinois-based fund reported 5,000 shares. Plante Moran Financial Limited Liability Corp reported 300 shares stake. Barclays Public Limited Company owns 29,925 shares for 0% of their portfolio. Morgan Stanley accumulated 0% or 15,860 shares. Tower Rech Limited Liability Company (Trc) holds 0% of its portfolio in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) for 526 shares. Finemark Savings Bank & Tru invested 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Sunbelt Secs has 0% invested in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Royal Retail Bank Of Canada accumulated 500 shares. The New Jersey-based Kcg has invested 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Creative Planning reported 0% of its portfolio in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Jfs Wealth Limited Liability Co holds 1,000 shares or 0% of its portfolio. State Bank Of Montreal Can invested in 1,600 shares or 0% of the stock.
